Skip to main content
SpringerLink
Log in

Eberconazole

(Eberconazol, Eberconazole Nitrate, WAS 2160)

  • Adis R&D Profile
  • Published:
Drugs in R & D Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II

Notes

  1. 1This profile has been selected from R&D Insight™, a pharmaceutical intelligence database produced by Adis International Ltd.

References

  1. Font E, del Palacio A, Cuétara S, et al. A phase II dose finding pilot study: topical treatment of tinea corporis and tinea cruris with eberconazole (WAS 2160) cream. Methods and Findings in Experimental and Clinical Pharmacology. 17 (Suppl A): 84, 1995

    Google Scholar 

  2. Del Palacio A, Ortiz FJ, Perez A, Pazos C, Garau M, et al. A double-blind randomized comparative trial: eberconazole 1% cream, versus clotrimazole 1% cream twice daily in Candida and dermatophyte skin infections. Mycoses. 44: 173–180, No. 5, 2001 del Palacio A, Univ Madrid, Hosp 12 Octubre, Dept Clin Microbiol, Carretera Andalucia, Km 5-4, E-28041 Madrid, SPAIN

    Article  PubMed  Google Scholar 

  3. Torres-Rodríguez JM, Mendez R, López-Jodra O, et al. In vitro susceptibilities of clinical yeast isolates to the new antifungal eberconazole compared with their susceptibilities to clotrimazole and ketoconazole. Antimicrobial Agents and Chemotherapy. 43: 1258–1259, May 1999

    PubMed  Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Eberconazole. Drugs R&D 3, 352–354 (2002). https://doi.org/10.2165/00126839-200203050-00011

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00126839-200203050-00011

Keywords

Search

Navigation